Crispr Therapeutics AG (CRSP) has released an update.
CRISPR Therapeutics AG has struck a deal with institutional investors to issue nearly 4 million of its common shares at $71.50 each, aiming to raise approximately $280 million before expenses. This move, part of an earlier shelf registration, is backed by standard legal provisions, including indemnity against liabilities under the Securities Act of 1933. The transaction underscores the company’s proactive steps in securing substantial funding for its future endeavors.
For further insights into CRSP stock, check out TipRanks’ Stock Analysis page.
